New triple-drug attack may crack tough breast cancer
NCT ID NCT07471815
First seen Mar 19, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests a new combination of drugs (camrelizumab, risedronate, and chemotherapy) in 30 women with triple-negative breast cancer. The goal is to see if adding risedronate can help overcome drug resistance and improve how well the cancer responds. The study is currently active but no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 158100, China
Conditions
Explore the condition pages connected to this study.